Log in

CMA congratulates Blackmores on investment in Australian manufacturing

24 Apr 2018 12:44 PM | Anonymous

Chief executive officer of Complementary Medicines Australia (CMA), Mr Carl Gibson, today welcomed the news that well-known industry member, Blackmores, has made a strategic investment in Australian manufacturing in a full acquisition of the world-class Catalent Australia tablet and soft-gel capsule manufacturing facility in Braeside, Victoria.

Read the release here

Call us on 02 6260 4022 or fax 02 6260 4122

Address: PO Box 450 Mawson, ACT 2607 Australia

Powered by Wild Apricot Membership Software